John Heymach
UT MD Anderson Cancer Center · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
5
all conditions, ClinicalTrials.gov
NIH grants tied to them
9
1 more share only the name and are not shown
Trial papers
103
PubMed author-name match
Trials
Studies that name John Heymach as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:50 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03800134 · A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerAstraZeneca · active not recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT03334617 · Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyAstraZeneca · active not recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT02950038 · Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)M.D. Anderson Cancer Center · withdrawn · Lung Cancer, Nonsmall Cell, Stage I · principal investigator
- Ph1/Ph2NCT02321540 · A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung CancerM.D. Anderson Cancer Center · completed · Lung Cancer · principal investigator
- Ph1NCT00621361 · Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer PatientsAstraZeneca · completed · Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung CancerR01CA287279 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2025 to 2026 · $679,129 awarded in 2026Same name and institution; not confirmed by an ID
- 10 Lung CancerP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2025 · $24,691 awarded in 2025Same name and institution; not confirmed by an ID
- Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic responseU01CA256780 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 to 2025 · $605,520 awarded in 2025Same name and institution; not confirmed by an ID
- Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitorsR01CA247975 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2024 · $549,195 awarded in 2024Same name and institution; not confirmed by an ID
- Therapeutic strategies against EGFR exon 20 mutant lung cancerR01CA234183 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2024 · $529,607 awarded in 2024Same name and institution; not confirmed by an ID
- Novel therapeutic approaches for enhancing anti-tumor immunity in SCLCU01CA213273 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2017 to 2021 · $551,067 awarded in 2021Same name and institution; not confirmed by an ID
- Therapeutic approaches for LKB1-deficient non-small cell lung cancerR01CA205150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2016 to 2020 · $605,252 awarded in 2020Same name and institution; not confirmed by an ID
- Overcoming Resistance to Anti-EGFR Therapy by Drug RepurposingR01CA190628 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2015 to 2019 · $498,667 awarded in 2019Grant number is on one of their registry trials
- Markers and therapeutic strategies for overcoming chemoradiotherapy resistanceR01CA168484 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2011 to 2015 · $286,702 awarded in 2015Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:50 UTC. The ranking covers the 200 most relevant of 103 PubMed records, and a shared surname and initials can bring in a namesake. All 103 on PubMed
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.Cancer Discov · 20181,464 citationsRCR 44.3
- 1,090 citationsRCR 44.6
- 936 citationsRCR 31.8
- Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.N Engl J Med · 2023770 citationsRCR 62.8
- Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.N Engl J Med · 2020725 citationsRCR 29.0
- The BATTLE trial: personalizing therapy for lung cancer.Cancer Discov · 2011649 citationsRCR 13.9
- 567 citationsRCR 26.2
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.Lancet Respir Med · 2021486 citationsRCR 24.7
- 409 citationsRCR 9.0
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.Cancer Discov · 2017358 citationsRCR 10.5